Abbisko: Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial
The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p- Statistically significant ...
中国日报网17h
German sci-tech company Merck to increase investments in China
German sci-tech giant Merck is very optimistic about its prospects in the Chinese market and will continue to strengthen its ...
AFP18h
Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial
Notably, the study also showed that treatment with pimicotinib provided statistically significant and clinically meaningful improvements in secondary endpoints associated with important patient ...
Morningstar20h
Merck KGaA's Cell-Tumor Drug Gets Positive Results in Late-Stage Trial
The drug is being developed by the Chinese biotech Abbisko Therapeutics Co. Merck KGaA holds commercial license for Pimicotinib in Chinese mainland, Hong Kong, Macau, and Taiwan, it said.